ribavirin / Generic mfg. - LARVOL DELTA

Respiratory syncytial virus (RSV) infection after CAR T-cell therapy (ASH 2025) - "RSV-specifictreatment (ribavirin ± corticosteroids/IVIG) was administered to 8 patients, all with severe infection,except one who received ribavirin for URTI...This is the first multicenter study with over 600 CAR-T recipients to systematically evaluate RSV-specificepidemiology following CAR-T therapy. The infection incidence and outcomes were comparable to thosereported after HCT, with 6% of recipients diagnosed and almost 30% progressing to LRTI, even beyondday +100. Older age and profound lymphopenia were associated with severe disease."

CAR T-Cell Therapy • Hematological Malignancies • Infectious Disease • Lymphoma • Multiple Myeloma • Pneumonia • Respiratory Diseases • Respiratory Syncytial Virus Infections • CD4

Redefining eIF4E's function in Acute Myeloid Leukemia: Implications for engraftment and survival (ASH 2025) - "We also confirmed these in vivofindings using different CRISPR/Cas9 clones.To validate the genetic perturbations, we pharmacologically target eIF4E using ribavirin inimmunodeficient mice transplanted with eIF4Ehigh primary AML cells...Consistently, ribavirintreated mice (n=4) lived approximately 51 days longer than vehicle treated mice (n=5), p=0.038.Altogether, we demonstrated that the depletion of eIF4E impairs engraftment within the niche andimproves overall survival in AML, highlighting an important role for eIF4E controlling migration andinvasion also in leukemia. This work opens new avenues for the development of combination therapeuticstrategies aimed to disrupt leukemia cell-niche interaction by targeting eIF4E in AML."

Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Solid Tumor • CD34 • EIF4E

Reactive oxygen species promotion drives auranofin's antiviral activity against hepatitis E virus. (PubMed, J Virol) - "The observed synergistic anti-HEV activity in vitro for combined treatment with both auranofin and ribavirin suggests a potential clinically effective combinational therapeutic approach. ROS promotion through auranofin or other means represents an underexplored antiviral strategy with potential for broad-spectrum activity against a range of viral diseases."

Journal • Infectious Disease • Inflammation

Venenum bufonis and its active constituents alleviate RSV-induced pneumonia in mice by suppressing macrophage infiltration and NLRP3 inflammasome activation. (PubMed, Virus Res) - "Mice were treated with Vb or ribavirin intraperitoneally for five days...Additionally, bufalin, cinobufagin, and resibufogenin were identified as likely bioactive constituents mediating Vb's therapeutic effects. This study provides a scientific basis for the potential application of Vb in the treatment of RSV-induced pneumonia."

Journal • Preclinical • Infectious Disease • Inflammation • Pneumonia • Respiratory Diseases • Respiratory Syncytial Virus Infections • IFNA1 • IFNG • IL1B • IL6 • NLRP3 • TNFA

Exploring therapeutic targets for cryptococcosis: in silico and in vitro testing for isocitrate lyase (ICL1) potential inhibitors. (PubMed, J Comput Aided Mol Des) - "Virtual screening of FDA-approved drugs selected five candidates: bufexamac, isoniazid, nifuraldezone, nifuroxazide, and ribavirin...This study provides novel insights into ICL1 inhibition and contributes to drug repurposing efforts for cryptococcosis. Despite high MIC values, isoniazid's antifungal activity warrants further investigation, particularly in synergistic combinations with existing antifungals."

Journal • Preclinical • Infectious Disease

EZH2 inhibition as a potential therapeutic avenue in the treatment of meningioma (SNO 2025) - "Furthermore, ribavirin treatment resulted in increased survival in an orthotopic skull base meningioma xenograft model.Our work demonstrates that EZH2 inhibition in meningioma results in decreased proliferation, induced cell cycle arrest and cell death, in vitro, while ribavirin treatment resulted in increased survival, in vivo, potentially via inhibition of EZH2. This work provides the framework for further investigation of EZH2 inhibition as targeted therapy in meningioma."

Brain Cancer • Meningioma • Solid Tumor • EZH2 • NF2 • SMARCB1

Chitosan nanoparticles loaded with ribavirin, carboplatin, and thyme oil downregulate SNQ2, ERG11, CDR1, and MDR1 in Candida strains. (PubMed, Sci Rep) - "qRT‒PCR confirmed notable downregulation of SNQ2 and ERG11 in C. glabrata and of CDR1 and MDR1 in C. tropicalis, with the most pronounced effects observed in the CS-NP-treated groups. CS-NPs significantly enhanced antifungal efficacy by reducing MIC values and downregulating resistance genes, highlighting their potential as effective drug delivery systems against Candida infections."

Journal • Candidiasis • Infectious Disease • ABCB1

Probenecid Treatment Inhibits Replication of the Edmonston Measles Virus Strain in Vero Cells. (PubMed, Viruses) - "MeV treatments may include vitamin A, ribavirin, the MeV vaccine, or human immunoglobulin for pregnant patients exposed to MeV but lacking immunity. This study indicates that pre-treatment with probenecid (prophylaxis) can inhibit the replication of the Edmonston MeV strain in VeroE6 cells (1.12 μM) and Vero-SLAM cells (1.03 μM), while treatment (1 h post-infection, hpi) inhibits replication in VeroE6 cells (1.32 μM) and Vero-SLAM cells (8.66 μM). These results suggest that probenecid is an effective, host-directed antiviral drug against MeV replication in vitro."

Journal • Infectious Disease • Measles • Mumps • Rubella

Pattern Recognition Algorithms in Pharmacogenomics and Drug Repurposing-Case Study: Ribavirin and Lopinavir. (PubMed, Pharmaceuticals (Basel)) - "We highlight successful approaches such as the machine learning-driven prediction of responders and the AI-assisted identification of repurposed drugs (exemplified by the case of baricitinib for COVID-19), alongside current limitations, including data scarcity, model interpretability, and translational gaps. Finally, we outline future directions for integrating multi-omics data, improving algorithmic interpretability, and enhancing the synergy between computational predictions and experimental validation. The insights presented highlight the promising role of pattern recognition algorithms in advancing precision medicine and accelerating drug discovery, while recognizing the challenges that must be addressed to fully realize their potential."

Biomarker • Journal • Review • Infectious Disease • Novel Coronavirus Disease

Ribavirin as a Dual-Function Electrolyte Additive for Dendrite-Free Zinc-Ion Batteries through Surface Adsorption and Coordination Structure Disruption. (PubMed, Langmuir) - "Benefiting from this dual function of coordination regulation and surface adsorption, the Zn//Cu asymmetric cells with ribavirin maintained consistent performance over 1000 charge/discharge cycles, still exhibiting a stable Coulombic efficiency of 98.6% at the 950th cycle, while the Zn//Zn symmetric cells demonstrated exceptionally stable cycling for over 2800 h at 1 mA·cm-2 and over 1050 h at 2 mA·cm-2, concurrently delivering enhanced Coulombic efficiency and superior rate performance. Furthermore, in V2O5-based full cells, ribavirin enhanced zinc-ion transport, improved specific capacity, and enabled stable cycling for over 2000 cycles."

Journal

Genetic determinants of efficacy of antiviral drugs revealed by genome-wide CRISPR screens. (PubMed, Antiviral Res) - "For ribavirin, adenosine kinase (ADK) and adenylsuccinate synthase (ADSS) were critical for nucleotide metabolism and bioactivation. Remdesivir uptake and activation depended on the transporter SLC29A3 and phosphoamidase HINT1, whereas favipiravir resistance was linked to NT5C2-mediated dephosphorylation. Viral replication assays in Huh7 cells validated that knockout of SLC29A3, HINT1, or NT5C2 significantly altered antiviral efficacy. This study delineates the genetic network governing nucleotide analog response, providing mechanistic insights and potential biomarkers for personalized antiviral therapy."

Journal • Hematological Malignancies • Lymphoma • Oncology • HINT1 • NT5C2

Sofosbuvir/Velpatasvir/Voxilaprevir Versus Sofosbuvir/Velpatasvir Plus Ribavirin in Patients With Hepatitis C Virus Genotype 3b and Compensated Cirrhosis: A Multicentre Randomized Controlled Trial. (PubMed, J Med Virol) - P4 | "Both regimens were well tolerated, with one serious adverse event in arm A. Compared to sofosbuvir/velpatasvir plus ribavirin, 12 weeks of sofosbuvir/velpatasvir/voxilaprevir treatment suggests a higher SVR proportion in DAA-naïve patients with HCV GT3b with compensated cirrhosis. Clinical Trial Number: NCT05467826."

Clinical • Journal • Fibrosis • Hepatitis C • Immunology • Infectious Disease • Inflammation

EZH2 inhibition as a potential therapeutic avenue in the treatment of meningioma (WFNOS 2025) - "Furthermore, ribavirin treatment resulted in increased survival in an orthotopic skull base meningioma xenograft model.Our work demonstrates that EZH2 inhibition in meningioma results in decreased proliferation, induced cell cycle arrest and cell death, in vitro, while ribavirin treatment resulted in increased survival, in vivo, potentially via inhibition of EZH2. This work provides the framework for further investigation of EZH2 inhibition as targeted therapy in meningioma."

Brain Cancer • Meningioma • Oncology • Solid Tumor • EZH2 • NF2 • SMARCB1

Co-Infection With Hepatitis E Virus and SARS-CoV-2 in a Lymphoma Patient. (PubMed, J Med Virol) - "Ribavirin was administered, but to date only temporarily led to HEV RNA undetectability in plasma when combined with immunosuppressive therapy interruption. This case and the three previous cases of coinfection with HEV and SARS-CoV-2 point out the possible deleterious effect of SARS-CoV-2 on the liver and the increased risk of such concurrent infections in immunocompromized patients."

Journal • Fibrosis • Hematological Malignancies • Immunology • Infectious Disease • Inflammation • Lymphoma • Novel Coronavirus Disease • Oncology • Respiratory Diseases

Navigating Measles Treatment in 2025: A Review on Vaccines, Medications, and Supplements. (PubMed, Pediatr Allergy Immunol Pulmonol) - "Topics included ribavirin, measles-mumps-rubella vaccine post-exposure prophylaxis, immune globulin, antibiotics, vitamin A, and cod liver oil supplements. Parents, caregivers, and policymakers considering these interventions are recommended to consult with health care providers and seek guidance from professional organizations regarding the effectiveness and safety of these treatments. Vaccination with the measles-mumps-rubella vaccine remains the most effective intervention to prevent measles, and efforts are urgently needed to achieve the requisite 95% vaccination rate to improve public health, confer herd immunity, and eradicate measles."

Journal • Infectious Disease • Measles • Mumps • Rubella

Chronic hepatitis E complicated by chylous ascites in an HIV-infected patient with previous disseminated MAC infection: a case report. (PubMed, ASM Case Rep) - "In this case report, we discuss the case of a 59-year-old gentleman living with HIV with a history of treated disseminated Mycobacterium avium complex infection treated 8 years prior, who initially presented with asymptomatic deranged liver enzymes and positive hepatitis E virus (HEV) RNA and subsequent recurrent chylous ascites, with good clinical and biochemical response to treatment with ribavirin. This case, to the best of our knowledge, is the second case of HEV infection presenting with chylous ascites and the first in a HIV-infected patient."

Journal • Fibrosis • Human Immunodeficiency Virus • Immunology • Infectious Disease • Inflammation • Transplantation

Viral hemorrhagic fevers - therapeutic trial advances and challenges. (PubMed, Expert Rev Anti Infect Ther) - "Key therapies like ribavirin for Crimean-Congo hemorrhagic fever and Lassa fever, along with monoclonal antibodies for Ebola and Marburg virus disease, have demonstrated clinical efficacy...The role of cytokine modulation and the growing potential of monoclonal antibodies offer new directions for treatment. Strengthening observational studies and expanding international collaboration are critical for improving patient outcomes and advancing therapeutic options for these deadly diseases."

Journal • Review • Ebola Virus Disease • Hematological Disorders • Infectious Disease

Solute Carrier Gene Polymorphism (SLC29A1) in Relation to Treatment Outcome and Hematological Changes in Chronic Hepatitis C Patients Treated With Direct Acting Antivirals Plus Ribavirin. (PubMed, J Med Virol) - "Regarding the change in hematological parameters revealed a highly significant decrease in delta Δ Hb, RBCs count and MCHC (p  G at SLC29A1 gene influences the severity of ribavirin-induced anemia, possibly mirroring erythrocyte uptake of ribavirin and that increases SVR in chronic hepatitis C patients receiving DAAs and ribavirin."

Journal • Hematological Disorders • Hepatitis C • Infectious Disease • Inflammation • SLC29A1

New insight into the epidemiological trends of respiratory syncytial virus infection and the underlying anti-respiratory syncytial virus mechanisms of andrographolide: integrating Global Burden of Disease database, network pharmacological analysis, and in vitro experiments. (PubMed, Microbiol Spectr) - "Notably, the inhibition of andrographolide on RSV viral adsorption was found to be better than ribavirin, and the corresponding key adsorption receptor was further identified as CX3CR1...Our study aimed to unveil the new global epidemiological trends and burdens caused by RSV to attract attention and elucidate the antiviral mechanisms of andrographolide against the RSV, presenting data that support its unique potential as a therapeutic agent capable of flexibly adapting to treat RSV infection. These findings pave the way for developing andrographolide as a new anti-RSV drug and expanding clinical therapeutic options."

HEOR • Journal • Preclinical • Infectious Disease • Inflammation • Respiratory Diseases • Respiratory Syncytial Virus Infections • CX3CR1 • IL1B • IL6 • TNFA • TXNIP

Advances in clinical application on nursing intervention for ribavirin-associated adverse events. (PubMed, Front Pharmacol) - "However, challenges persist, such as individual patient variability, resource constraints, and insufficient evidence-based guidelines. Future research should focus on establishing standardized nursing protocols, conducting multicenter clinical studies, exploring intelligent nursing approaches, and enhancing nursing expertise to optimize ribavirin-related adverse event management."

Adverse events • Journal • Gastrointestinal Disorder • Hematological Disorders • Hepatitis C • Infectious Disease • Inflammation • Respiratory Diseases • Respiratory Syncytial Virus Infections

CVID Enteropathy Associated With Chronic Norovirus Infection: Background, Clinical Features, and Therapeutic Aspects. (PubMed, Rev Med Virol) - "Intravenous or subcutaneous immunoglobulin replacement fails to adequately protect against gastrointestinal infections, and off-label antivirals such as ribavirin, nitazoxanide, or interferon alpha have yielded inconsistent results. We also present our experience with a patient successfully treated with immunoglobulin therapy administered via nasogastric tube, leading to clinical remission, nutritional recovery, and viral clearance. Recognising norovirus as a key etiological factor in CVID enteropathy emphasises the need to conduct systematic studies and evidence-based therapeutic approaches."

Journal • Review • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammation • Primary Immunodeficiency

Chronic hepatitis E and hepatitis E seroprevalence in immunosuppressed patients: a prospective study. (PubMed, Transl Gastroenterol Hepatol) - "HEV IgG seroprevalence in our immunosuppressed population is 9.9%. Chronic HEV was found in 0.6% of the patients, all kidney transplanted and having required ribavirin treatment."

Journal • Bone Marrow Transplantation • Hematological Disorders • Hematological Malignancies • Infectious Disease • Inflammation • Lymphoma • Oncology • Solid Organ Transplantation • Transplantation

Niosomes as a versatile nanocarrier for antiviral agents: Enabling delivery of both hydrophilic and hydrophobic drugs. (PubMed, Int J Pharm) - "In this study, we optimized a thin-film hydration method to produce stable niosomes, capable of encapsulating three antiviral agents: mycophenolic acid, ribavirin, and curcumin...Combination analysis of mycophenolic acid and curcumin revealed synergistic effects on cell viability but antagonistic interactions in antiviral assays, highlighting the importance of assessing drug combinations across different biological contexts. These findings position niosomes as a promising platform for antiviral delivery and provide a solid basis for future optimization and translational studies."

Journal • Herpes Simplex

Multi-inflammatory index as a novel predictive and prognostic marker in patients with Crimean-Congo haemorrhagic fever. (PubMed, Trans R Soc Trop Med Hyg) - "MIIs, particularly MII-1, serve as independent predictors of mortality in CCHF patients. Early evaluation of MII levels may aid risk stratification and clinical decision-making. Future studies should explore the dynamic changes in these indices and their impact on treatment outcomes."

Biomarker • Journal • Infectious Disease

Under the Radar of Standard Testing: First Documented Cases of Chronic Hepatitis E in Patients with Multiple Myeloma Receiving T-cell Redirecting Therapies (DGHO 2025) - "Of the 4 patients treated with ribavirin, three developed chronic HEV infection. All 3 were concurrently receiving T-cell-redirecting therapies: one had undergone ciltacabtagene autoleucel treatment six months earlier, and the other 2 were on bispecific antibodies targeting BCMA and GPRC5D... The study included 7 patients with MM (5 men, 2 women), aged between 48 and 78 years. HEV infection was diagnosed after a median interval of 46.7 months following initial MM diagnosis. Median HEV-RNA levels in peripheral blood were 48,865 IU/mL."

Clinical • Hematological Malignancies • Hepatology • Infectious Disease • Inflammation • Multiple Myeloma • Otorhinolaryngology • Vertigo